share_log

大行评级|花旗:对药明合联开启30日上行催化观察 目标价41港元

Gelonghui Finance ·  Jul 26 03:22

格隆汇7月26日|花旗发表报告指,由于药明合联项目需求强劲,预期上半年将录得理想业绩,料盈利按年增长57%,而市场预测增长为48%。另外,管理层亦表示订单趋势良好。花旗对药明合联开启30日上行催化观察,目标价41港元,评级“买入”。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment